Leading pharmaceutical organizations such as Biogen, Novartis, and EMD Serono are pioneering new portfolio management approaches that enable agility without compromising strategic vision. This article explores how these top players rethink portfolio evaluation, define success, and leverage forecasting and scenario planning to optimize value in a complex regulatory landscape.
Moreover, optimizing for value today means accounting for geographic reimbursement differences, evolving patient needs, and pipeline redundancies-all while ensuring organizational agility. In this environment, portfolio leaders are transforming traditional governance structures and enabling faster, insight-driven pivots.
As regulatory hurdles grow more complex and competition accelerates, successful portfolio strategies must go beyond static planning. The shift is toward dynamic decision-making frameworks that integrate real-time data, cross-functional alignment, and risk-adjusted prioritization. Scenario-based modeling, cross-portfolio trade-off analyses, and early-stage asset valuation are becoming standard practices among top-tier companies.
In this rapidly evolving landscape, the ability to swiftly adapt not only enhances competitive advantage but also ensures that companies remain aligned with the ultimate goal of improving patient outcomes. By fostering a culture of continuous learning and agility, biopharma organizations can better anticipate market shifts, regulatory changes, and scientific breakthroughs. This proactive approach empowers them to allocate resources more effectively, reduce time-to-market, and sustain innovation pipelines that address unmet medical needs globally.
Key Tensions: Innovation vs. Commercial Pressure
Biopharma companies traditionally operate in an environment where innovation cycles are long, R&D is costly, and regulatory hurdles are high. At the same time, commercial pressures demand quicker returns and responsiveness to market changes.
This creates a fundamental tension:
- Innovation requires bold investments in novel therapies that may take years to reach the market.
- Commercial pressure demands a focus on profitable products and quick wins to satisfy shareholders.
Balancing these priorities is no longer a luxury but a necessity. Firms like Novartis are adopting portfolio strategies that dynamically allocate resources between breakthrough innovations and incremental improvements to existing products.
This fundamental tension forces biopharma companies to continuously evaluate and re-prioritize their project portfolios. They must identify which innovative therapies have the potential for high long-term impact while ensuring that existing products continue to generate steady revenue streams. Achieving this balance requires not only rigorous data analysis but also flexible decision-making frameworks that can quickly adapt to emerging scientific discoveries, regulatory changes, and market demands.
Moreover, companies are increasingly leveraging cross-functional collaboration to align R&D, commercial, and regulatory teams around shared goals. This holistic approach helps ensure that investment decisions are both strategically sound and operationally feasible, reducing time-to-market and maximizing overall portfolio value.
Ultimately, firms that master this dynamic resource allocation are better positioned to sustain innovation, satisfy shareholder expectations, and deliver meaningful patient outcomes in an increasingly competitive environment.
A study conducted by the Pharmaceutical Education and Research Institute (PERI) and members of the Pharmaceutical Research and Manufacturer’s Association (PhRMA) sought to identify how various approaches to pharmaceutical project management affect organizational effectiveness. Results of the study are presented below.
- Two emerging trends in pharmaceutical project management
- Virtual project: Contains project work off-site and at a considerable distance from management. Many firms can share the ownership of the project, and employees and nonemployees share project tasks, according to Project Management Institute.
Defining Success: KPIs That Matter Now
Success metrics in biopharma portfolio management have evolved beyond traditional financial indicators. Top companies now focus on a blend of quantitative and qualitative KPIs, including:
- Time to market-accelerating development phases without compromising quality.
- Pipeline robustness-measuring the diversity and potential of development projects.
- Probability of technical and regulatory success (PTRS)-integrating risk profiles early in evaluation.
- Return on innovation investment-balancing R&D spend against expected long-term value.
- Patient impact-increasingly important for value-based healthcare models.
For example, EMD Serono emphasizes patient-centric KPIs aligned with real-world outcomes to justify continued investment in complex indications.
How Forecasting & Scenario Planning Shape Decision-Making
In the highly dynamic biopharma industry, companies face constant uncertainty driven by regulatory changes, rapid technological advancements, and fluctuating market demands. To navigate these complexities, forecasting and scenario planning have become indispensable tools for informed decision-making.
Forecasting involves using historical data, industry trends, and advanced analytics to predict future events or market conditions. This enables companies to anticipate key milestones such as regulatory approval timelines or shifts in patient needs.
Scenario planning takes forecasting a step further by allowing organizations to model multiple plausible futures instead of relying on a single predicted outcome. Through this approach, companies evaluate different scenarios-ranging from best-case to worst-case-to understand the potential risks and opportunities each might present. This method provides a structured way to stress-test strategic plans under varying conditions and uncertainties.
Leading pharmaceutical companies leverage sophisticated forecasting models to:
- Predict Regulatory Timelines and Potential Hurdles: Regulatory agencies’ requirements and approval processes can vary significantly by region and indication. Accurate forecasting helps companies anticipate delays or additional data requests, enabling them to prepare contingency plans.
- Evaluate Competitor Pipelines and Market Entry Scenarios: Understanding what competitors are developing and when they might launch new products helps companies position their own portfolios competitively and identify white space opportunities.
- Assess Pricing and Reimbursement Environments: Since healthcare systems differ globally in how they price and reimburse drugs, forecasting aids in evaluating market access challenges and financial viability across geographies.
- Simulate Outcomes Based on Investment Levels or Trial Results: By modeling the impact of different levels of investment or trial outcomes, companies can make informed decisions about whether to advance, pause, or discontinue development programs.
For example, Biogen utilizes scenario planning extensively to stress-test portfolio decisions against multiple scenarios-best-case, base-case, and worst-case. This enables the company to remain flexible, shifting resources and adjusting timelines as new information arises or market conditions evolve.
Real-Life Examples from Leading Companies
The pharmaceutical industry operates in a highly dynamic environment, where market forces, regulatory shifts, and technological innovations continually reshape the landscape. Forecasting and scenario planning equip companies with the tools to anticipate these changes and adjust strategies proactively. To illustrate how these strategic approaches play out in practice, it is insightful to examine recent real-world developments and trends among leading pharma players.
In 2023, 55 new molecular entities were approved by the FDA, the second-highest count in the past 30 years. This cohort was nearly double what it was in 2022, which is likely to be because of issues such as workflow disruptions and bandwidth problems caused by the global Covid-19 pandemic have improved.
Several drug patents expired in 2023, including AbbVie’s Humira and Johnson & Johnson’s Stelara. Looking ahead to 2024 and beyond, the pharma industry is set to face further shake-ups in the coming years with many more blockbuster drugs from Bristol Myers Squibb, Novartis and other companies are set to face their first generic or biosimilar competitors in the largest global pharma market, the US. As always, the patent expirations should create quite a disturbance for many of the top players.
Mergers and acquisitions (M&A) are also gradually changing the marketplace and some of the largest drugmakers have been strengthened through joining forces with or being bought out by other businesses. According to GlobalData’s Deals Database, in the global pharmaceutical industry, there were 430 M&A deals announced at the start of 2024 worth a total value of $68.8bn. There are not expected to be any megadeals that combine large conglomerates this year, but large pharma companies will likely continue to pursue with acquiring or partnering with biotechs to offset losses from patent expires, according to Proclinical.
Agile Frameworks in a Regulatory-Heavy Environment
Adapting agile methodologies, common in tech industries, to the rigid biopharma sector is challenging but increasingly feasible:
- Incremental decision cycles: Frequent portfolio assessments replace static annual planning, allowing companies to pivot quickly based on the latest data and market feedback. This continuous evaluation helps identify risks early and capitalize on emerging opportunities without waiting for lengthy review periods.
- Cross-functional teams: Collaborative governance structures bring together experts from R&D, regulatory affairs, commercial, and finance to accelerate decision-making. Breaking down silos encourages diverse perspectives, reduces delays, and aligns strategic objectives across departments.
- Digital tools: Advanced analytics platforms provide real-time data to inform portfolio shifts, offering predictive insights and scenario modeling capabilities. Leveraging machine learning and AI supports better forecasting and risk assessment, enhancing the quality and speed of decisions.
- Regulatory engagement: Early and ongoing dialogue with authorities ensures alignment on development pathways, compliance expectations, and potential hurdles. Proactive communication reduces surprises, facilitates faster approvals, and fosters a collaborative relationship with regulators.
In today’s rapidly evolving pharmaceutical industry, companies face unprecedented challenges in navigating complex regulatory landscapes while striving to bring innovative therapies to market. The convergence of technological advancements, changing patient needs, and evolving regulatory frameworks has created a dynamic environment that demands agility and adaptability. This blog explores how pharmaceutical companies can implement agile regulatory strategies to thrive in this ever-changing landscape, according to Freyr.
Together, these agile frameworks empower biopharma companies to remain flexible and responsive despite complex regulatory environments. They help balance innovation speed with compliance rigor, ultimately accelerating time-to-market while managing risk effectively. Embracing agility also positions organizations to better adapt to evolving healthcare landscapes and patient needs, ensuring sustainable competitive advantage in a fast-changing industry.